Publications

Authors:

Vita, Giovanni; Pollini, Demetrio; Canozzi, Andrea; Papola, Davide; Gastaldon, Chiara; Correll, Christoph U; Barbui, Corrado; Ostuzzi, Giovanni

Title:

Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

Elettronico

Referee:

Sì

Name of journal:

PSYCHIATRY RESEARCH

ISSN of journal:

0165-1781

N° Volume:

340

Number or Folder:

116124

:

Elsevier Science Ireland Limited:PO Box 85, Limerick Ireland:011 353 61 709600, 011 353 61 61944, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: 011 353 61 709114

Page numbers:

1-9

Keyword:

Acute symptoms; Antipsychotics; Long-acting injectable antipsychotics; Psychopharmacology; Psychosis; Schizophrenia-spectrum disorders

Short description of contents:

To assess the effect of Long-acting injectable (LAI) antipsychotics in acutely ill patients, we systematically searched major databases for randomized controlled trials (RCTs) comparing LAIs with other LAIs, oral antipsychotics, or placebo in acutely symptomatic adults with schizophrenia-spectrum disorders. Data were analyzed with a random-effects network meta-analysis. Co-primary outcomes were efficacy (mean change in psychopathology rating scales) and acceptability (all-cause discontinuations) at study endpoint. Of 25 RCTs, 19 studies tested second-generation LAIs (SGA-LAIs) and six first-generation LAIs (FGA-LAIs). Due to a disconnected network, FGA-LAIs were analyzed separately, with poor data quality. The SGA-LAIs network included 8,418 individuals (males=63%, mean age=39.3 years). All SGA-LAIs outperformed placebo in reducing acute symptoms at study endpoint (median follow-up=13 weeks). They were more acceptable than placebo with the only exception of olanzapine, for which no differences with placebo emerged. Additionally, we distinguished between different LAI formulations of the same antipsychotic to explore potential pharmacokinetic differences. Most formulations outperformed placebo in the very short-term (2 weeks or less), regardless of the need for initial oral supplementation. SGA-LAIs are evidence-based treatments in acutely ill individuals with schizophrenia-spectrum disorders. Findings support the use of SGA-LAIs to manage psychopathology and improve adherence right from the acute phases of illness.

Web page:

https://doi.org/10.1016/j.psychres.2024.116124

Product ID:

140936

Handle IRIS:

11562/1135047

Last Modified:

October 12, 2024

Bibliographic citation:

Vita, Giovanni; Pollini, Demetrio; Canozzi, Andrea; Papola, Davide; Gastaldon, Chiara; Correll, Christoph U; Barbui, Corrado; Ostuzzi, Giovanni, Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis «PSYCHIATRY RESEARCH» , vol. 340 , n. 116124 , 2024 , pp. 1-9

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo